IE 11 is not supported. For an optimal experience visit our site on another browser.

Progenics to Host First Quarter 2011 Financial Results Conference Call and Webcast May 10

TARRYTOWN, N.Y., May 9, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it will host a conference call and webcast to discuss its financial results for the first quarter of 2011 on Tuesday May 10, 2011 at 8:30 a.m. ET.
/ Source: GlobeNewswire

TARRYTOWN, N.Y., May 9, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it will host a conference call and webcast to discuss its financial results for the first quarter of 2011 on Tuesday May 10, 2011 at 8:30 a.m. ET.

To participate in the conference call, please dial 888-262-8720 (domestic) or 913-312-1520 (international). A telephone replay of the call will be available for one week following. To access the replay, please dial 888-203-1112 (domestic) or 719-457-0820 (international). The access code for both the live and recorded conference call is 9277781. The live webcast will be available on the Events page of the Company's website and subsequently archived for 30 days.

Progenics Pharmaceuticals, Inc., of Tarrytown, NY USA, is a biopharmaceutical company with programs in gastroenterology, oncology and virology focused on innovative therapeutics for patients with debilitating conditions and life-threatening diseases. Progenics' first commercialized therapy is RELISTOR(R) (methylnaltrexone bromide), a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness. Progenics has exclusively licensed Salix Pharmaceuticals, Ltd. to continue development and commercialization of RELISTOR in worldwide markets other than Japan, where Ono Pharmaceutical Co., Ltd. has an exclusive license to develop and commercialize subcutaneous RELISTOR. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 1 testing for treatment of prostate cancer, and preclinical stage, novel antibodies to toxins produced by C. difficile bacteria.

Please Note: The information in this press release may contain projections and other forward-looking statements regarding future events. Such statements are just predictions and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and results of clinical trials and other development activities involving pharmaceutical products; the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs; market acceptance for approved products; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting risks and litigation. More information concerning Progenics and such risks and uncertainties is available on its website, as well as in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing this information as of this date and does not undertake any obligation to update or revise this information, whether as a result of new information, future events or circumstances or otherwise.

Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release.

CONTACT: Progenics Pharmaceuticals, Inc. Amy Martini 914-789-2816 amartini@progenics.com Scienta Communications Aline Schimmel 312-238-8957 aschimmel@scientapr.com